Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2016 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2015 financial results on Thursday, March 10, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, March 10, 2016 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company’s financial results and provide a general business update.
The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of the company’s website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 50136086.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
Company Contact: Heather Rowe Investor Relations 415-365-5737 [email protected]
